Is CAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CAVA ($143.52) is trading above our estimate of fair value ($100.37)
Significantly Below Fair Value: CAVA is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CAVA?
Key metric: As CAVA is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for CAVA. This is calculated by dividing CAVA's market cap by their current
revenue.
What is CAVA's PS Ratio?
PS Ratio
18x
Sales
US$913.49m
Market Cap
US$16.33b
CAVA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: CAVA is expensive based on its Price-To-Sales Ratio (18x) compared to the US Hospitality industry average (1.6x).
Price to Sales Ratio vs Fair Ratio
What is CAVA's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
CAVA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
18x
Fair PS Ratio
3.3x
Price-To-Sales vs Fair Ratio: CAVA is expensive based on its Price-To-Sales Ratio (18x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst CAVA forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
US$143.52
US$156.46
+9.0%
14.7%
US$195.00
US$110.00
n/a
13
Nov ’25
US$131.53
US$122.33
-7.0%
13.5%
US$155.00
US$90.00
n/a
12
Oct ’25
US$122.43
US$114.75
-6.3%
11.5%
US$135.00
US$90.00
n/a
12
Sep ’25
US$114.04
US$111.55
-2.2%
9.9%
US$125.00
US$90.00
n/a
11
Aug ’25
US$84.48
US$89.27
+5.7%
10.5%
US$105.00
US$72.00
n/a
11
Jul ’25
US$95.27
US$86.73
-9.0%
8.2%
US$95.00
US$72.00
n/a
11
Jun ’25
US$92.55
US$86.20
-6.9%
8.2%
US$94.00
US$72.00
n/a
10
May ’25
US$67.45
US$65.49
-2.9%
9.6%
US$74.00
US$53.00
n/a
12
Apr ’25
US$68.40
US$62.81
-8.2%
5.7%
US$66.00
US$53.00
n/a
11
Mar ’25
US$58.30
US$61.40
+5.3%
8.7%
US$66.00
US$50.00
n/a
10
Feb ’25
US$49.41
US$46.60
-5.7%
13.2%
US$55.00
US$35.00
n/a
10
Jan ’25
US$42.98
US$45.40
+5.6%
13.2%
US$55.00
US$35.00
n/a
10
Dec ’24
US$36.22
US$42.89
+18.4%
14.1%
US$55.00
US$35.00
n/a
9
Nov ’24
US$31.95
US$43.56
+36.3%
15.3%
US$55.00
US$33.00
US$131.53
9
Oct ’24
US$30.63
US$49.63
+62.0%
11.5%
US$58.00
US$40.00
US$122.43
8
Sep ’24
US$43.82
US$51.00
+16.4%
9.3%
US$58.00
US$45.00
US$114.04
7
Aug ’24
US$56.99
US$45.86
-19.5%
5.9%
US$50.00
US$42.00
US$84.48
7
Analyst Forecast: Target price is less than 20% higher than the current share price.